Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
AbCellera Biologics Inc (AbCellera) is a biotechnology company that discovers and develops next-generation therapeutic antibodies for cancer, metabolic and endocrine conditions, and autoimmune disorders. The company’s pipeline products include ABCL635 which treats vasomotor symptoms (VMS); and ABCL575 for atopic dermatitis (AD). It utilizes T-Cell Engagers platform to address challenging tumor types by incorporating novel CD3, co-stimulatory, and multispecific modalities. The company’s therapeutic areas include endocrine and metabolic conditions, oncology, and inflammation and autoimmunity diseases. It operates across Australia, the UK, the US and Canada. AbCellera is headquartered in Vancouver, British Columbia, Canada.
Headquarters
Canada
Address
150 W 4th Avenue, Vancouver, British Columbia, V6E4E5
Website
www.abcellera.com
Telephone
1 604 5599005
No of Employees
562
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABCL (NASD)
Revenue (2024)
$75.1M
160.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
10.1%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
65.5%
(2024 vs 2023)
* As of and is in US$
AbCellera Biologics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| TABCL635: Vasomotor Symptoms (VMS) |
| ABCL575: Atopic Dermatitis (AD) |
| ABCL688: Autoimmunity |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | AbCellera Biologics Inc | Pfizer Inc | AbbVie Inc | Sanofi | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | France | United States of America |
| City | Vancouver | New York City | North Chicago | Paris | Thousand Oaks |
| State/Province | British Columbia | New York | Illinois | Ile-de-France | California |
| No. of Employees | 562 | 75,000 | 57,000 | 76,493 | 31,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carl L.G. Hansen, Ph.D | Chief Executive Officer; Chairman; President | Executive Board | 2012 | 50 |
| Veronique Lecault, Ph.D | Director; Chief Technology Officer | Executive Board | 2018 | 40 |
| Andrew Booth | Chief Financial Officer | Senior Management | 2019 | 51 |
| Tryn Stimart | Privacy Officer; Chief Compliance Officer; Chief Legal Officer; Secretary | Senior Management | 2023 | 55 |
| Sarah Noonberg, M.D., Ph.D | Chief Medical Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer